ReviewAdvanced drug delivery reviews2021
Advances in gene-based vaccine platforms to address the COVID-19 pandemic.
Review in Advanced drug delivery reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The influence of hypoxia on tissue regeneration in oral and maxillofacial surgery - a systematic review.Clinical oral investigations · 2026Pooled it
- Article
- Immunization with virus-like vesicle-based COVID-19 vaccine induces robust systemic and mucosal immunity.NPJ vaccines · 2025Article
- Ministring DNA (msDNA): a novel linear covalently-closed DNA with enhanced stability for gene and cell therapy applications.Scientific reports · 2025Article
- Article
- Designing of an innovative conserved multiepitope subunit vaccine targeting SARS-CoV-2 glycoprotein and nucleoprotein through immunoinformatic.Scientific reports · 2025Article
- Recent Approaches for the Topical Treatment of Psoriasis Using Nanoparticles.Pharmaceutics · 2024Review
- Transfection of hypoxia-inducible factor-1α mRNA upregulates the expression of genes encoding angiogenic growth factors.Scientific reports · 2024Article
- Constructing Nucleic Acid Delivering Lipoproteoplexes from Coiled-Coil Supercharged Protein and Cationic Liposomes.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Coronavirus Anatomy and Its Analytical Approaches for Targeting COVID-19.Advances in experimental medicine and biology · 2024Review
- Clinical Analysis and Applications of mRNA Vaccines in Infectious Diseases and Cancer Treatment.Cureus · 2023Review
- Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination.JCI insight · 2023Article
- Vaccine Hesitancy and the Concept of Trust: An Analysis Based on the Israeli COVID-19 Vaccination Campaign.Minerva · 2023Article
- Recent Advancements in Electroporation Technologies: From Bench to Clinic.Annual review of biomedical engineering · 2023Review
- Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19).Archives of microbiology · 2023Review
- Review
- Functional nucleic acids as potent therapeutics against SARS-CoV-2 infection.Cell reports. Physical science · 2023Review
- SARS-CoV-2 sublingual vaccine with RBD antigen and poly(I:C) adjuvant: Preclinical study in cynomolgus macaques.Biology methods & protocols · 2023Article
- Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine.Frontiers in immunology · 2023Article
- Improved transfer efficiency of supercharged 36 + GFP protein mediate nucleic acid delivery.Drug delivery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The novel betacoronavirus, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has spread across the globe at an unprecedented rate since its first emergence in Wuhan City, China in December 2019. Scientific communities around the world have been rigorously working to develop a potent vaccine to combat COVID-19 (coronavirus disease 2019), employing conventional and novel vaccine strategies. Gene-based vaccine platforms based on viral vectors, DNA, and RNA, have shown promising results encompassing both humoral and cell-mediated immune responses in previous studies, supporting their implementation for COVID-19 vaccine development. In fact, the U.S. Food and Drug Administration (FDA) recently authorized the emergency use of two RNA-based COVID-19 vaccines. We review current gene-based vaccine candidates proceeding through clinical trials, including their antigenic targets, delivery vehicles, and route of administration. Important features of previous gene-based vaccine developments against other infectious diseases are discussed in guiding the design and development of effective vaccines against COVID-19 and future derivatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.